Status:
UNKNOWN
Buccal Misoprostol and Intravenous Tranexamic Acid During Emergent Cesarean Delivery
Lead Sponsor:
hany farouk
Conditions:
Cesarean Section Complications
Eligibility:
FEMALE
18-45 years
Phase:
NA
Brief Summary
Purpose to evaluate the effects of buccal misoprostol with or without intravenous tranexamic acid (TA) in comparison with placebo on reducing post-partum hemorrhage in pregnant women undergoing emerge...
Detailed Description
The American Congress of Obstetricians and Gynecologists (ACOG) defines postpartum hemorrhage (PPH) as the loss of more than 1,000 mL after cesarean delivery. In the majority of cases, uterine atony i...
Eligibility Criteria
Inclusion
- age \>18 years, singleton pregnancy, term gestation and decision made for a cesarean section in labor
Exclusion
- multiple gestations
- placenta praevia and placental abruption
- undergoing cesarean section with general anesthesia
- women undergoing cesarean section at less than 37 weeks of gestation--with a severe medical disorder
- allergy to tranexamic acid or misoprostol
- refuse to consent
- elective cesarean section
Key Trial Info
Start Date :
January 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2021
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT03777696
Start Date
January 1 2019
End Date
January 31 2021
Last Update
February 18 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aswan University
Aswān, Egypt, 81528